JP2023527525A - インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法 - Google Patents

インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法 Download PDF

Info

Publication number
JP2023527525A
JP2023527525A JP2022571117A JP2022571117A JP2023527525A JP 2023527525 A JP2023527525 A JP 2023527525A JP 2022571117 A JP2022571117 A JP 2022571117A JP 2022571117 A JP2022571117 A JP 2022571117A JP 2023527525 A JP2023527525 A JP 2023527525A
Authority
JP
Japan
Prior art keywords
ifn
rna
oligonucleotide duplex
immunostimulatory oligonucleotide
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527525A5 (https=
Inventor
ロンロン シ
ハイチン バイ
ドナルド イー． イングバー
クリスタル ユーリ オー
レイチェル プランティル－バウン
Original Assignee
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ filed Critical プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Publication of JP2023527525A publication Critical patent/JP2023527525A/ja
Publication of JP2023527525A5 publication Critical patent/JP2023527525A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022571117A 2020-05-22 2021-05-21 インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法 Pending JP2023527525A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063029199P 2020-05-22 2020-05-22
US63/029,199 2020-05-22
US202063082742P 2020-09-24 2020-09-24
US63/082,742 2020-09-24
PCT/US2021/033617 WO2021237067A1 (en) 2020-05-22 2021-05-21 Interferon- inducing oligonucleotide duplexes and methods of use

Publications (2)

Publication Number Publication Date
JP2023527525A true JP2023527525A (ja) 2023-06-29
JP2023527525A5 JP2023527525A5 (https=) 2024-04-16

Family

ID=78707688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571117A Pending JP2023527525A (ja) 2020-05-22 2021-05-21 インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法

Country Status (4)

Country Link
US (1) US20230242918A1 (https=)
EP (1) EP4153752A4 (https=)
JP (1) JP2023527525A (https=)
WO (1) WO2021237067A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159383A1 (en) * 2021-01-19 2022-07-28 President And Fellows Of Harvard College Engineered nucleic acids targeting long noncoding rna involved in pathogenic infection
CN118948865B (zh) * 2024-10-15 2025-03-25 佛山大学 维奈妥拉abt-199在制备防治轮状病毒的药物中的应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535043A (ja) * 2000-03-10 2003-11-25 ダイナバックス テクノロジーズ コーポレイション 免疫調節ポリヌクレオチド配列を用いてウイルス感染症を予防および治療する方法
CN1590545A (zh) * 2003-06-04 2005-03-09 杭州新瑞佳生物医药技术开发有限公司 攻击SARS病毒mRNA分子的小干扰核糖核酸分子（SiRNA）及应用
US20050119203A1 (en) * 2001-11-02 2005-06-02 Klinikum Der Universitaet Regensburg Smad7 inhibitors for the treatment of cns diseases
US20060178334A1 (en) * 2005-02-04 2006-08-10 City Of Hope Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon
JP2010500011A (ja) * 2006-08-08 2010-01-07 ガンサー ハートマン ５’リン酸オリゴヌクレオチドの構造および使用
US20140155462A1 (en) * 2011-04-22 2014-06-05 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibitions of egfr by double-stranded rna
US20140315983A1 (en) * 2011-11-04 2014-10-23 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of met by double stranded rna
CN104630223A (zh) * 2014-12-22 2015-05-20 淮阴工学院 包含POKEMON基因的siRNA的运输载体颗粒及其制备方法
US20150315584A1 (en) * 2009-01-26 2015-11-05 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
JP2015532270A (ja) * 2012-09-27 2015-11-09 ライニッシェ フリードリッヒ ヴィルヘルムス ウニヴェルジテート ボン 新規のｒｉｇ−ｉリガンドおよびそれらの生産方法
JP2016164148A (ja) * 2010-08-30 2016-09-08 スプリング バンク ファーマシューティカルズ，インコーポレイテッド 治療薬としてオリゴヌクレオチド類縁体の設計
CN111139241A (zh) * 2020-04-03 2020-05-12 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
WO2021167841A1 (en) * 2020-02-18 2021-08-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842459B2 (en) * 2004-01-27 2010-11-30 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
EP1773857A4 (en) * 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
DK2405002T3 (en) * 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Compositions and methods for oligonukleotidformuleringer
WO2012079115A1 (en) * 2010-12-14 2012-06-21 Commonwealth Scientific And Industrial Research Organisation Immunostimulatory oligonucleotides
EP3581654B1 (en) * 2013-12-27 2021-03-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535043A (ja) * 2000-03-10 2003-11-25 ダイナバックス テクノロジーズ コーポレイション 免疫調節ポリヌクレオチド配列を用いてウイルス感染症を予防および治療する方法
US20050119203A1 (en) * 2001-11-02 2005-06-02 Klinikum Der Universitaet Regensburg Smad7 inhibitors for the treatment of cns diseases
CN1590545A (zh) * 2003-06-04 2005-03-09 杭州新瑞佳生物医药技术开发有限公司 攻击SARS病毒mRNA分子的小干扰核糖核酸分子（SiRNA）及应用
US20060178334A1 (en) * 2005-02-04 2006-08-10 City Of Hope Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon
JP2010500011A (ja) * 2006-08-08 2010-01-07 ガンサー ハートマン ５’リン酸オリゴヌクレオチドの構造および使用
US20150315584A1 (en) * 2009-01-26 2015-11-05 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
JP2016164148A (ja) * 2010-08-30 2016-09-08 スプリング バンク ファーマシューティカルズ，インコーポレイテッド 治療薬としてオリゴヌクレオチド類縁体の設計
US20140155462A1 (en) * 2011-04-22 2014-06-05 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibitions of egfr by double-stranded rna
US20140315983A1 (en) * 2011-11-04 2014-10-23 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of met by double stranded rna
JP2015532270A (ja) * 2012-09-27 2015-11-09 ライニッシェ フリードリッヒ ヴィルヘルムス ウニヴェルジテート ボン 新規のｒｉｇ−ｉリガンドおよびそれらの生産方法
CN104630223A (zh) * 2014-12-22 2015-05-20 淮阴工学院 包含POKEMON基因的siRNA的运输载体颗粒及其制备方法
WO2021167841A1 (en) * 2020-02-18 2021-08-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
CN111139241A (zh) * 2020-04-03 2020-05-12 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOWIE A G, TRENDS IN IMMUNOLOGY, vol. V28 N4, JPN5009011823, 2007, US, pages 147 - 150, ISSN: 0005609038 *
HORNUNG VEIT, SCIENCE, vol. V314 N5801, JPN5009011825, 10 November 2006 (2006-11-10), US, pages 994 - 997, ISSN: 0005609036 *
PICHLMAIR, SCIENCE, vol. V314 N5801, JPN5009011824, 10 November 2006 (2006-11-10), US, pages 997 - 1001, ISSN: 0005609037 *

Also Published As

Publication number Publication date
EP4153752A1 (en) 2023-03-29
WO2021237067A9 (en) 2023-04-06
EP4153752A4 (en) 2025-10-01
US20230242918A1 (en) 2023-08-03
WO2021237067A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
AU2011329668B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
AU2006304205C1 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8853177B2 (en) Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
AU2008227128B2 (en) Conjugates of synthetic TLR agonists and uses therefor
US11382966B2 (en) Method for designing RIG-I ligands
US8426375B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20160215042A1 (en) Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
CA2752694A1 (en) Synthetic rna-based agonists of tlr7
JP2009510096A (ja) アダプターオリゴヌクレオチドを用いたｔｌｒ媒介免疫応答の調節
US10273484B2 (en) Double-stranded RNA conjugates and their use
US8383598B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP2023527525A (ja) インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法
US20090098063A1 (en) Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
CA3177685A1 (en) Tlr7/8 antagonists for the treatment of coronavirus infections
US20250121055A1 (en) Interferon- inducing complexes and rna duplexes and methods of use
US9688993B2 (en) Toll-like receptor 9 antagonist and methods of use thereof
EP4188546A2 (en) Treatment of viral diseases
Bian Precision Adjuvant Design Enabling Tailored Nanoparticle Immunization Platforms for Oxycodone and Other Substance Abuse Vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230621

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230621

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417